• The company’s rebranding reflects Izotropic’s refined corporate positioning and emphasizes its focus on key people across the healthcare ecosystem
• Izotropic’s strategic positioning becomes even more critical when considering the magnitude of the opportunity ahead
• Izotropic has the exclusive global licensing rights to breast CT technology, and IzoView is the commercial model

As Izotropic (CSE: IZO) (OTCQB: IZOZF) positions itself to capture a share of the $8.7 billion global breast imaging market projected by 2030 (ibn.fm/tRIr4), the company has unveiled a strategic brand transformation that signals its readiness to commercialize two decades of breakthrough medical research. Izotropic holds exclusive global licensing rights to revolutionary breast CT technology and is advancing its flagship IzoView Breast CT Imaging System from proven science to real-world medical impact, offering what could be the first-in-class solution for more accurate breast cancer screening and diagnosis.

The company’s redesigned website reflects Izotropic’s refined corporate positioning and introduces a modern, unique, visual identity that emphasizes its focus on key people — patients, clinicians and stakeholders — across the healthcare ecosystem. This strategic transformation represents a pivotal moment for the company as it transitions from development to market readiness, requiring a brand presence that can effectively communicate its value proposition to diverse stakeholders across the global healthcare landscape.

The rebranding effort centers around establishing Izotropic as a leader in advanced breast imaging technology, with the company introducing a compelling corporate tagline that encapsulates its mission. “Advanced Imaging. Accessible Care.” appears in materials and corporate communications to communicate the Izotropic’s commitment to innovations that can scale across diverse care settings. This messaging directly addresses one of the most significant challenges in modern healthcare: making advanced diagnostic technologies accessible beyond traditional academic medical centers and major hospital systems.

Izotropic’s strategic positioning becomes even more critical when considering the magnitude of the opportunity ahead. The global breast imaging market is projected to reach approximately $8.7 billion by 2030, driven by demand for earlier, more accurate cancer detection. The company’s unique position in this expanding market stems from its exclusive licensing rights to proven technology that has undergone extensive development and validation.

The foundation of Izotropic’s commercial strategy rests on two decades of scientific advancement and clinical validation. Breast CT technology has been built, tested and refined in clinical trials for academic research purposes over the last 20 years. Izotropic has the exclusive global licensing rights to breast CT technology, and IzoView is the commercial model. This extensive development history provides the company with a significant competitive advantage, as the underlying technology has already demonstrated its clinical utility through rigorous academic research.

The company’s flagship product, the IzoView Breast CT Imaging System (ibn.fm/KTPtI), has received its own distinctive positioning within the broader brand architecture. The company’s flagship product, the IzoView system, carries a new distinct tagline: Engineered for Today’s Challenges and Tomorrow’s Care Models. The new tagline highlights the system’s ability to address unmet needs in breast imaging, while capturing its alignment with evolving industry trends driving market expansion. This product-specific messaging recognizes that healthcare systems are undergoing rapid transformation, with increasing emphasis on value-based care, improved patient outcomes and operational efficiency.

The comprehensive website redesign serves as more than just a digital facelift; it represents a strategic communication platform designed to support the company’s commercialization objectives. The site provides an accessible, centralized platform for engaging with Izotropic’s story, solutions and strategy as the company builds toward commercialization. The enhanced digital presence features multiple content types designed to engage different stakeholder groups, each with distinct information needs and decision-making processes.

Content enrichment has been a key focus of the rebranding initiative, with the company developing materials specifically designed to communicate complex medical technology in accessible terms. The updated web presence features streamlined navigation and enriched content, including new presentations, video materials and messaging that communicates Izotropic’s value proposition, clinical direction and strategic focus. This multimodal approach recognizes that different stakeholders prefer different types of information consumption, from detailed technical specifications for clinical researchers to accessible overviews for potential investors.

The leadership team driving this transformation brings together expertise across multiple critical disciplines required for successful medical device commercialization. Izotropic is led by a multidisciplinary team of experts in medical imaging, clinical research, engineering, and commercialization. Together, they are advancing IzoView from proven science to real-world impact. This diverse skill set is essential for navigating the complex regulatory, clinical, and commercial challenges inherent in bringing innovative medical devices to market.

The timing of this rebranding initiative reflects Izotropic’s strategic preparation for the next phase of its corporate development. As the company works toward regulatory approvals and commercial launch, having a professional, cohesive brand presence becomes increasingly important for stakeholder engagement, partnership development, and market positioning. The healthcare industry, in particular, demands high levels of professionalism and credibility from technology providers, making brand perception a critical component of commercial success.

The rebranding also positions Izotropic to better communicate its unique value proposition in an increasingly competitive landscape. With a first-in-class device and a focused clinical strategy, Izotropic offers a unique opportunity to invest at the forefront of a fast-growing sector. This position emphasizes both the innovative nature of the company’s technology and its strategic approach to market entry, appealing to investors seeking exposure to transformative healthcare technologies.

Looking ahead, the refreshed brand identity provides Izotropic with a foundation for sustained growth and market expansion. Izotropic invites investors, media, and stakeholders to explore the new site and follow the Company’s progress as it works to deliver transformative solutions to the global breast imaging market. This invitation represents more than marketing language; it reflects the company’s confidence in its technology, strategy, and ability to execute on its commercial objectives.

The comprehensive rebranding initiative demonstrates Izotropic’s commitment to professionalization and market readiness as it advances toward commercialization of its revolutionary breast imaging technology. Through strategic positioning, enhanced digital presence, and clear messaging, the company has established a brand foundation capable of supporting its ambitious growth objectives in the expanding global breast imaging market.

For more information, visit the company’s website at www.IzoCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF

• The U.S. remains heavily dependent on China for rare earth processing and refined components critical to defense, electronics and clean-energy applications.
• An independent evaluation confirmed that RapidSX can separate both light and heavy REEs using proven conventional chemistry but dramatically faster kinetics. 
• Ucore’s broader vision includes disrupting China’s control over the REE industry by introducing scalable, high-efficiency separation technology.

The race to secure rare earth elements has become a matter of both economic survival and national security for the United States, as China continues to dominate the global supply chain for these critical resources. At the center of America’s push to break free from this dependence is Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), whose RapidSX(TM) technology offers a faster, more efficient way to separate rare earths and build a resilient domestic supply chain.

The U.S. remains heavily dependent on China for rare earth processing and refined components critical to defense, electronics and clean-energy applications. China currently refines about 90% of the world’s rare earths, giving it outsized influence over the global supply chain (https://ibn.fm/1itJK). The country also dominates the critical permanent magnet market, producing an estimated 85–90% of global supply as of 2023 (https://ibn.fm/s8iMr). These magnets are essential for technologies ranging from electric vehicles to wind turbines, making China’s dominance a major strategic concern for U.S. policymakers and industry leaders. 

In addition, the United States doesn’t have adequate refining infrastructure. China processes nearly all heavy rare earths and most light rare earth refining, meaning the U.S. must export raw ore for processing and then re-import refined products. This highlights the critical need for Ucore and its RapidSX technology (https://ibn.fm/qSw3u). Ucore’s proprietary tech is a patent-pending, environmentally friendly, column-based solvent extraction process that separates both light and heavy REEs more efficiently and with a smaller footprint than traditional mixer-settler solvent extraction systems.

An independent evaluation by AGHS, commissioned by Ucore, confirmed that RapidSX can separate both light and heavy REEs using proven conventional chemistry but dramatically faster kinetics. This enables a potential two to three times smaller plant footprint and a more than 50% reduction in capital costs, with operating cost savings of about 20% compared to traditional processes, all while being scalable from 1,000 to more than 10,000 tonnes per annum (https://ibn.fm/3YPiR).

At the demonstration scale, RapidSX is already in action. Ucore operates a RapidSX Commercial Demonstration Plant in Kingston, Ontario, funded in part through a U.S. Department of Defense (“DoD”) contract valued at $4 million (https://ibn.fm/NAShw). The company has also secured an additional C$4.28 million from the government of Canada to support commercialization of RapidSX using North American feedstocks.

Ucore’s strategy extends to the U.S., with its planned Louisiana Strategic Metals Complex (“SMC”) in Alexandria, which aims to process both heavy and light mixed rare earth concentrates for North American supply resilience. Automation plays a key role, as RapidSX utilizes programmable logic controllers and hundreds of sensors in its 52-stage demonstration platform to enable precise, efficient operations (https://ibn.fm/89gwC).

Ucore’s broader corporate vision emphasizes disrupting China’s nearly complete control over the REE industry, particularly the $15.7 billion-per-year rare earth oxide supply chain, by introducing scalable, high-efficiency separation technology to North America (https://ibn.fm/7Hpzy). The company’s focus on scalable extraction, beneficiation and separation technologies positions it as an advanced-technology contributor in the critical metals sector.

China’s recent export restrictions on seven key medium and heavy rare earth elements—including samarium, terbium, and dysprosium—have further illuminated the urgency of establishing an independent U.S. supply chain. Ucore CEO Pat Ryan, P.Eng., emphasized that these developments highlight the “urgent need for a robust and independent rare earth supply chain in North America” and that RapidSX offers a transformative solution to the challenge.

By providing a viable path toward smaller, faster, more cost-effective REE separation that is backed by independent evaluation, automation and government support, RapidSX helps fill a glaring gap in the U.S. industrial ecosystem. Its modular design offers flexibility and scalability, making it well-suited not only for the Louisiana SMC but future strategic metals complexes in Canada and Alaska and even for proprietary feed sources such as Ucore’s Bokan-Dotson Ridge project.

For more information, visit www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• The three projects, Sydney, Brooklyn, and Petpeswick, will generate a combined 12.4 MW DC of clean energy.
• Funding is provided by Nova Scotia’s Department of Energy and managed by Net Zero Atlantic.
• PowerBank is the lead developer for the owner, working alongside local partner Trimac Engineering.
• The projects are part of Canada’s first Community Solar Program, targeting 80% renewable energy by 2030.
• PowerBank has completed over 100 MW of projects and holds a pipeline exceeding 1 GW across North America.

Disseminated on behalf of PowerBank Corporation

PowerBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., secured $1.74 million in government funding to support three community solar projects across Nova Scotia. According to the company’s announcement, the Sydney, Brooklyn, and Petpeswick projects, once operational, will generate a total of 12.4 megawatts (“MW”) of direct current (“DC”) electricity, feeding clean power directly into the local grid (https://ibn.fm/e9gKm).

The funding is being distributed under the Nova Scotia Department of Environment and Climate Change, administered by the Department of Energy and managed by Net Zero Atlantic. The breakdown of funding is as follows:

• $340,000 for the Sydney Solar Project
• $440,000 for the Petpeswick Solar Project
• $960,000 for the Brooklyn Solar Project

Ownership of the projects is shared between AI Renewable Flow-through Fund (48%) and non-profit or Indigenous partners such as the Potlotek First Nation (52%). PowerBank will act as lead developer and builder, partnering with Trimac Engineering, a Nova Scotia-based firm.

The projects fall under the Nova Scotia Community Solar Program (“CSP”), the first of its kind in Canada. The program supports the province’s goal of generating 80% of electricity from renewable sources by 2030 and achieving a net-zero grid by 2035.

Through CSP, community members, including renters and businesses, can subscribe to local solar projects and receive credits on their electricity bills, typically saving around $0.02 per kilowatt-hour (“kWh”). This model makes solar accessible without the need for installing panels on homes or commercial properties.

The initiative is also expected to stimulate local economic activity by supporting engineering, construction, and long-term operations within the province.

For PowerBank, the grant underscores its strategy of expanding beyond U.S. markets into Canada. PowerBank positions itself as a high-growth renewable energy developer. To date, the company has completed more than 100 MW of solar capacity and is advancing a development pipeline of over one gigawatt. Its portfolio spans distributed and community solar, as well as battery energy storage systems (“BESS”).

The company has already delivered over 100 MW of community solar projects in the United States and sees Nova Scotia as a key growth opportunity as community solar programs develop across Canada. Dr. Richard Lu, President and CEO of PowerBank, said the funding will help ensure the long-term success of these initiatives:

“This funding from Net Zero Atlantic will go far towards the development of long-lasting solar projects that bring clean energy and energy savings to Nova Scotia,” said Dr. Lu. “With over a decade of proven experience in solar development and operations—including community solar, commercial and industrial installations, and other government-led initiatives—PowerBank brings the expertise needed to the successful implementation of Nova Scotia’s Community Solar projects.”

For more information, visit the company’s website at https://PowerBankCorp.com.

This report contains forward looking information. Please refer to the press release entitled “Community Solar Projects Receive $1.74 Million Grant from Net Zero Atlantic” and dated August 19, 2025, for additional details on the information, risks and assumptions.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• CEO reports confidence about late-stage rare disease pipeline and upcoming key development milestones.
• Soligenix’s recent accomplishments reflect substantial momentum across its specialized biotherapeutics and public health solutions business segments.
• The company’s pipeline diversification strategy extends beyond CTCL treatment to encompass multiple therapeutic areas.

With pivotal phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies advancing through late-stage development, Soligenix (NASDAQ: SNGX) stands at the threshold of potentially transforming treatment paradigms for rare diseases affecting millions of underserved patients worldwide. The Soligenix pipeline includes a novel photodynamic drug therapy, along with other innovative drug and vaccine technology, to tackle medical challenges where conventional treatments have failed to deliver meaningful solutions, recently reported on its progress so far this year (https://ibn.fm/1dhGj).

“As we quickly approach the latter part of 2025 into 2026, the company remains confident about its late-stage rare disease pipeline and upcoming key development milestones,” said Soligenix CEO and president Christopher J. Schaber in the update. “These include top-line results from our phase 2a clinical trial in mild-to-moderate psoriasis with SGX302 (synthetic hypericin) before year end, as well as continued clinical update for the ongoing investigator-initiated study (‘IIS’) evaluating extended HyBryte(TM) (synthetic hypericin) treatment for up to 54 weeks in patients with early-stage cutaneous T-cell lymphoma (‘CTCL’).

“Further, we anticipate top-line results in 2026 from our actively enrolling confirmatory phase 3 study of HyBryte for early-stage CTCL, where we plan to provide an enrollment update later this year,” Schaber continued. “Recently, we were also pleased to announce the successful completion of our phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet’s disease, having achieved the study objective of demonstrating biological efficacy in this difficult to treat chronic disease.”

The company’s recent accomplishments reflect substantial momentum across its specialized biotherapeutics segment, positioning Soligenix at a critical inflection point in its development trajectory. The most significant advancement centers on the company’s flagship HyBryte (“SGX301” or synthetic hypericin sodium) program, which represents a novel photodynamic therapy utilizing safe visible light for the treatment of CTCL. This innovative approach addresses a significant unmet medical need in oncology, where traditional treatment options remain limited and often associated with substantial side effects.

The clinical promise of HyBryte extends beyond initial efficacy data to encompass sustained therapeutic benefits that distinguish it from existing treatment options. Analysis of post-treatment data from the open-label study comparing HyBryte to Valchlor(R) (mechlorethamine) demonstrated continued improvement in HyBryte-treated patients and their individual lesions even after stopping treatment. This durability of response represents a significant clinical advantage, potentially reducing treatment burden and improving quality of life for patients with this challenging condition.

Soligenix’s commitment to comprehensive clinical development is further demonstrated through the formation of a European Medical Advisory Board in November 2024 (https://ibn.fm/yzssW). This strategic initiative provides additional medical and clinical guidance as the company advances its confirmatory phase 3 multicenter, double-blind, placebo-controlled study. The international expertise represented by this advisory board reflects the global commercial potential of HyBryte and the company’s intention to pursue regulatory approvals across multiple jurisdictions.

The company’s pipeline diversification strategy extends beyond CTCL treatment to encompass multiple therapeutic areas through its synthetic hypericin technology platform. The expansion of synthetic hypericin (“SGX302”) into psoriasis treatment represents a significant market opportunity, with mild-to-moderate psoriasis affecting millions of patients worldwide (https://ibn.fm/qruXo). The ongoing phase 2 study in this indication, with top-line results anticipated in the second half of 2025, could unlock substantial additional commercial potential for the synthetic hypericin platform.

The financial foundation supporting these clinical initiatives reflects disciplined capital allocation while maintaining sufficient runway for critical development milestones. With approximately $6.5 million in cash as of July 1, 2025, the company has secured operating runway through the first quarter of 2026, enabling completion of several pivotal clinical milestones without immediate financing pressure. This financial position provides strategic flexibility as the company evaluates partnership opportunities, merger and acquisition possibilities, government grants, and potential financing options to advance its late-stage pipeline.

The company’s revenue structure reflects its dual business model, combining clinical development activities with government-funded programs supporting national biodefense initiatives. While revenues decreased to $0.1 million for 2024 compared to $0.8 million in the prior year, this fluctuation primarily reflects the timing of government grant funding rather than fundamental program changes. The company continues to receive government funding for its public health solutions segment, which includes vaccine development programs targeting critical national security threats.

Research and development expenses increased to $5.2 million in 2024 compared to $3.3 million in the prior year, reflecting the company’s commitment to advancing multiple clinical programs simultaneously. The increase primarily related to preliminary costs associated with the Behçet’s Disease Phase 2 study initiation and the second confirmatory Phase 3 CTCL trial, demonstrating active progress across the development pipeline.

The strategic positioning of Soligenix’s pipeline addresses multiple high-value therapeutic areas with significant unmet medical need. The combination of novel photodynamic therapy technology, innovative vaccine platforms, and first-in-class inflammatory disease treatments creates a diversified portfolio with multiple paths to commercial success and substantial value creation potential.

Looking ahead, the company anticipates several critical inflection points that could significantly impact valuation and strategic positioning. The expected top-line results from multiple phase 2 studies in the second half of 2025, combined with ongoing phase 3 CTCL trial progress toward 2026 readout, provide multiple near-term catalysts for value creation and potential partnership opportunities.

For investors and stakeholders seeking exposure to innovative rare disease therapeutics with significant commercial potential, Soligenix’s current positioning represents a compelling opportunity at a critical development inflection point, supported by a diversified pipeline addressing multiple high-value therapeutic areas.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• GlobalTech balances internal innovation with strategic acquisitions to accelerate growth and long-term value creation.
• The company’s flagship platforms span multiple high-growth domains including enterprise productivity, e-commerce, digital lending, and compliance.
• Its majority stake in WorldCall Telecom Ltd. supports infrastructure-led value creation in Pakistan’s telecommunications sector.
• Strategic alliances with regional players such as Omantel anchor GlobalTech’s expansion into key international markets like the Middle East.

GlobalTech (OTC: GLTK) is a U.S.-based technology holding company specializing in artificial intelligence (“AI”), big data, and digital infrastructure. Advancing toward a Nasdaq listing, the company balances internal innovation with strategic acquisitions to accelerate growth and long-term value creation.

GlobalTech’s diversified portfolio spans AI-powered solutions for enterprise productivity, e-commerce, retail, digital lending, compliance, and other high-growth domains. Flagship platforms include ThrivoAI, Cadnz, Baseball Blitz, Talina, ProtoEd, BillCare, Giftio, and EntityScan. The company also holds a majority stake in WorldCall Telecom Ltd., extending its telecommunications presence in Pakistan and supporting infrastructure-led value creation.

To strengthen market reach, GlobalTech continues to evaluate technology-centric acquisitions while also expanding through strategic regional alliances. Its partnership with significant regional players like Omantel anchors growth in the Middle East, a key gateway market. At the same time, the company’s Center of Excellence (“CoE”) and #GTCTalks knowledge platform position it as a thought leader in emerging technologies.

Supported by a seasoned leadership team and a disciplined execution model, GlobalTech is building sustainable momentum across global AI and big data markets, with the governance, innovation, and agility required to capture outsized opportunities in the digital economy.

For more information, visit the company’s website at www.GlobalTechCorporation.com.

NOTE TO INVESTORS: The latest news and updates relating to GLTK are available in the company’s newsroom at https://ibn.fm/GLTK

• The agreement is a milestone in VMAR’s strategic evolution from a specialized electric propulsion manufacturer to a comprehensive marine retail powerhouse.
• The strategic importance of this partnership becomes evident when considering Florida’s dominant position in the American boating market.
• This distribution agreement follows Vision Marine’s transformative June 2025 acquisition of Nautical Ventures.

In a bold move to dominate America’s most lucrative boating market, Vision Marine Technologies (NASDAQ: VMAR) has locked in exclusive distribution rights for premium Nimbus Boats throughout Florida’s West Coast, positioning the company to capture a significant slice of the state’s massive $6.4 billion annual powerboat sales (https://ibn.fm/T0MHH). Vision Marine Technologies is revolutionizing the marine industry as a pioneering technology company that manufactures zero-emission electric boats while operating North America’s first integrated electric propulsion and multi-brand retail empire, bridging the gap between traditional boating and the sustainable future of watercraft.

The agreement represents a significant milestone in Vision Marine’s strategic evolution from a specialized electric propulsion manufacturer to a comprehensive marine retail powerhouse. Through Nautical Ventures, its Florida-based dealership network, Vision Marine has signed a letter of intent (“LOI”) with Nimbus Boats USA to exclusively distribute Nimbus powerboats across Florida’s West Coast region. This agreement, expected to be finalized by March 31, 2026, will authorize Nautical Ventures to promote, sell and service Nimbus’s complete product lineup, including their Tender, Commuter, Weekender and Coupe series beginning this month.

The strategic importance of this partnership becomes evident when considering Florida’s dominant position in the American boating market. Florida remains the largest U.S. market for new powerboats, engines and accessories, generating $6.4 billion in 2023 sales. This market leadership position makes Florida an essential territory for any marine company seeking to establish meaningful market presence and revenue growth in the recreational boating sector.

Vision Marine’s approach to this expansion reflects a calculated strategy to broaden its product portfolio while strengthening its geographical presence in critical markets. The Nimbus distribution agreement aims to capture demand in what the company identifies as the fast-growing, adventure-style boat segment, complementing Vision Marine’s existing electric propulsion offerings with traditional powerboat options that appeal to diverse customer preferences and use cases.

This distribution agreement follows Vision Marine’s transformative June 2025 acquisition of Nautical Ventures, a strategic move that created what the company describes as North America’s first electric boat propulsion and multibrand retail company (https://ibn.fm/BdrQg). This acquisition fundamentally altered Vision Marine’s business model, expanding the company beyond its original focus on electric propulsion technology to encompass comprehensive retail and service operations across the East Coast of the United States.

The foundational technology that distinguishes Vision Marine in the marketplace centers on its flagship E-Motion(TM) 180E system, described as a fully industrialized, high-voltage electric outboard system designed specifically for recreational boating applications (https://ibn.fm/fU3WZ). This advanced powertrain delivers continuous 180 HP performance while producing zero emissions, representing more than two decades of engineering development in electric marine propulsion. 

The company’s mission extends beyond simple product manufacturing to encompass broader environmental stewardship and industry transformation. Vision Marine is leading the innovation of the traditional boating market by only manufacturing electric boats producing zero emissions, keeping the natural environment completely clean. This environmental focus aligns with growing consumer awareness and regulatory pressure regarding emissions and environmental impact in recreational activities.

Vision Marine’s technological innovation represents a significant advancement in marine propulsion capabilities, addressing historical limitations that have restricted electric boating adoption. Electric marine propulsion has been around for some time, but never at this level of power. This advanced technology harnesses the full potential of high voltage, delivering powerful performance with zero emissions in a noiseless and odorless experience. This combination of performance and environmental benefits positions the company to capture market share as the recreational boating industry transitions toward more sustainable technologies.

The strategic positioning achieved through the Nautical Ventures acquisition along with the Nimbus distribution agreement creates a unique market position for Vision Marine. Through Nautical Ventures’ retail operations, Vision Marine now offers both traditional internal combustion engine boats and next-generation electric propulsion solutions, providing a comprehensive product range that meets current market demands while positioning the company for future market evolution.

This dual approach addresses a critical challenge facing electric vehicle adoption across transportation sectors: the need to maintain customer choice and operational flexibility during technological transition periods. By offering both traditional and electric options, Vision Marine can serve customers at various stages of adoption readiness while building market presence and customer relationships that support long-term electric propulsion adoption.

The company’s vision encompasses broader industry transformation, positioning Vision Marine as “the future of marine propulsion and a driving force in the conservation of waterways.” This insightful positioning reflects recognition that successful technology adoption requires not just superior products but also comprehensive market infrastructure, customer support and strategic partnerships that facilitate widespread adoption.

Looking ahead, the Nimbus distribution agreement represents more than a simple product line extension; it demonstrates Vision Marine’s commitment to building sustainable competitive advantages through strategic market positioning, geographic expansion, and comprehensive customer service capabilities. As the recreational boating industry continues evolving toward more sustainable technologies, Vision Marine’s integrated approach positions the company to capture value across multiple market segments while advancing environmental conservation objectives.

For more information, visit www.VisionMarineTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at https://ibn.fm/VMAR

• D-Wave launches initiative to develop advanced cryogenic packaging for both gate-model and annealing quantum processors.
• The program will expand multichip packaging capabilities, manufacturing equipment, and processes.
• Initiative leverages expertise from NASA’s Jet Propulsion Laboratory (“JPL”) for superconducting bump-bond technology.
• The goal is to increase interconnectivity and scalability for architectures reaching 100,000 qubits.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has announced a strategic development program to expand its capabilities in cryogenic packaging, designed to advance and scale both gate-model and annealing quantum processors. The initiative underscores the company’s focus on hardware innovation to support its long-term technology roadmap (https://ibn.fm/WU30l).

Cryogenic packaging – the housing and interconnection of quantum processor components in extremely low-temperature environments – plays a central role in performance and scalability. In quantum computing, packaging must not only handle ultra-low temperatures but also be compatible with ultra-low magnetic fields and ensure uninterrupted superconductivity from on-chip circuits to external wiring.

According to D-Wave, the new initiative will expand its multichip packaging capabilities, add advanced manufacturing equipment, and refine processes to support the development of larger and more complex quantum processors.

A key element of the effort is D-Wave’s collaboration with NASA’s Jet Propulsion Laboratory (“JPL”), managed by Caltech. The company is incorporating JPL’s superconducting bump-bond process, which allows end-to-end superconducting interconnects between chips. This technology could be essential for both scaling D-Wave’s existing annealing architecture and advancing its fluxonium-based gate-model systems.

D-Wave sees superconducting bump bonds as a potential enabler for higher-density control and better interconnectivity across multichip quantum processor architectures. The ability to maintain superconductivity through these connections is vital for maintaining ultra-low temperature operation and high qubit coherence, both of which are essential for scaling toward error-corrected systems.

Beyond chip-to-chip connections, the initiative will target increases in circuit density for superconducting printed circuit boards (“PCBs”). These boards form the backbone of D-Wave’s quantum systems, and higher-density circuits can help pack more processing power into each system. 

Dr. Trevor Lanting, D-Wave’s chief development officer, noted that high-performance packaging is essential for scaling both annealing and gate-model systems. “We believe this strategic initiative will allow us to further extend our leadership position in quantum systems technology development and support our exciting and aggressive product roadmap on the path to 100,000 qubits,” he said.

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers — the world’s largest — feature QPUs with sub-second response times and can be deployed on-premises or accessed through our quantum cloud service, which offers 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

• Lantern Pharma completed enrollment in its LP-184 Phase 1a trial and is preparing Phase 1b/2 studies in cancers with large market potential.
• Early patient responses across LP-184, LP-284, and LP-300 trials highlight clinical activity in difficult-to-treat cancers.
• Intellectual property expanded with new European patent allowance for LP-284 and publication of blood-brain barrier prediction patent.
• Enhancements to RADR(R), the company’s AI platform, include public launch of predictBBB.ai(TM) and a new drug combination module.
• Lantern ended Q2 with $15.9 million in cash and expects its runway to extend into mid-2026.
• R&D expenses declined year-over-year, reflecting disciplined cost control while advancing multiple trials.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, reported second-quarter 2025 results while outlining clinical progress, intellectual property gains, and new developments in its RADR(R) artificial intelligence platform. The company continues to advance multiple oncology drug candidates aimed at high-value markets, supported by a balance sheet that management says provides funding into June 2026 (https://ibn.fm/xEtvR).

The company has finished enrolling 65 patients in its Phase 1a trial of LP-184, a synthetic acylfulvene drug candidate. The study established both the maximum tolerated dose and recommended Phase 2 dose, enabling planned Phase 1b/2 trials in recurrent triple negative breast cancer (“TNBC”) and recurrent bladder cancer.

LP-184 has already received Fast Track designations for glioblastoma and TNBC, along with several Rare Pediatric Disease designations. Preclinical work at Johns Hopkins supported the pediatric potential of LP-184 by showing extended survival in mouse models of atypical teratoid rhabdoid tumors. Lantern estimates that LP-184 could address a market worth between $10 and $12 billion annually if approved.

Lantern Pharma also noted that LP-284 produced a complete metabolic response in a 41-year-old patient with aggressive diffuse large B-cell lymphoma who had exhausted several prior treatment regimens including CAR-T therapy. These results support the company’s belief that LP-284 could play a role in treating refractory lymphomas, a market estimated at $4 billion annually.

During the quarter, Lantern reported individual patient responses that may bolster the clinical case for its pipeline. In the HARMONIC(TM) trial of LP-300 combined with chemotherapy, a 70-year-old non-smoker with advanced non-small cell lung cancer achieved a complete response after multiple prior therapies had failed. The trial has now completed enrollment in Japan, where never-smoker lung cancer has a relatively high prevalence. Further data from the HARMONIC(TM) trial are expected in September, particularly from the Asian expansion cohort in Japan and Taiwan.

Lantern strengthened its patent coverage during the quarter. The European Patent Office issued a notice of allowance for a composition of matter patent covering LP-284, adding to protection already secured in the U.S. and Japan. Additional applications are pending in several other regions.

Separately, the company announced the publication of an international patent application covering its machine learning solution for predicting blood-brain barrier permeability. The patent could extend protection for 20 years from filing if granted.

Lantern Pharma continues to build out its RADR(R) AI platform, which it positions as a tool for accelerating oncology drug discovery and development. Two notable modules were highlighted this quarter.

The first is predictBBB.ai(TM), launched publicly with accuracy metrics exceeding 90% in predicting whether small molecules can cross the blood-brain barrier. This has direct implications for central nervous system drug development, where very few compounds are successful.

The second is a drug combination prediction module that draws on peer-reviewed research and clinical trial data to forecast effective cancer therapy combinations. Initially, the focus will be on DNA damaging agents and DNA repair inhibitors, a segment where billions of dollars are invested annually.

Lantern has indicated that selected RADR(R) modules may be opened to the wider oncology research community, creating opportunities for collaboration and potential revenue diversification.

For the quarter ending June 30, Lantern reported cash, cash equivalents and marketable securities of $15.9 million. Management expects this to provide operating runway into at least mid-2026.

Research and development expenses fell to $3.1 million from $3.9 million a year earlier, while general and administrative expenses were $1.6 million. The company had 10.8 million shares outstanding at the end of the quarter, with no warrants issued.

CEO Panna Sharma said the combination of patient responses in clinical trials and enhancements to the AI platform marked an important stage in Lantern Pharma’s evolution. The company plans to continue advancing its trials while expanding RADR(R) into functional modules for broader use in oncology research.

“This quarter we observed complete responses in patients across two of our clinical trials, delivering meaningful patient benefit and providing further validation of both the mechanisms and therapeutic potential of our drug candidates,” said Sharma. “Simultaneously, our team is transforming our AI platform into functional, accessible modules for the broader oncology community. These parallel advances mark a pivotal inflection point in our clinical and technological evolution, reinforcing our fiscally disciplined, AI-driven approach to addressing critical unmet patient needs with a clear pathway to commercialization and value creation.”

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

• Lottery.com rebrands as SEGG Media Corporation (NASDAQ: SEGG, LTRYW), signaling the closing of legacy challenges and the start of a growth-focused media, gaming, and sports strategy
• The company now operates through three synergistic verticals: Sports, Entertainment, and Lottery, aiming to redefine global fan experiences
• SEGG Media has stabilized operations, secured a $300 million equity facility, and is preparing for international expansion in motorsports, esports, and immersive media

The convergence of sports, entertainment, and technology is accelerating, and companies once limited by legacy models are racing to transform into platforms designed for modern fans. Fueled by shifting demographics, immersive content demand, and the rise of ethical, tech-enabled gaming, the space is ripe for disruption. That backdrop makes the recent rebrand of Lottery.com Inc. into SEGG Media (NASDAQ: SEGG, LTRYW) a timely and strategic evolution, not just in name but in mission and operational architecture.

From Lottery.com to SEGG Media: A Structural and Strategic Pivot

On July 8, 2025, SEGG Media made its debut under the ticker symbol SEGG, formally completing its transformation from Lottery.com into a diversified, forward-facing sports and entertainment company. The rebrand, while symbolic, is more than cosmetic; it represents a definitive close to previous operational and financial hurdles and opens the door to a bold new vision centered on immersive fan engagement and global media reach.

The new corporate identity – Sports Entertainment Gaming Global Media – is designed to encapsulate the company’s broadened focus and expanded footprint. With support from stakeholders and a newly structured organization, SEGG Media is positioning itself to compete on the world stage as a next-generation media conglomerate.

Three Vertical Pillars Powering a Unified Platform

Central to SEGG Media’s transformation is a three-pronged vertical strategy:

• Sports.com: Anchoring the company’s sports division, Sports.com is being developed into a global hub for all things sport. This includes sim racing, live immersive streaming, motorsports, football, esports, and athlete-led content initiatives. The vertical also houses Sports.com Studios and Sports.com Media, both focused on original content, documentaries, and storytelling formats designed to engage a younger, digital-native audience.
• Entertainment: Still in the process of expansion, these vertical leverages AI-driven event streaming, music, fashion, and fan interaction. Following the anticipated completion of the acquisition of DotCom Ventures, Inc., properties such as Concerts.com and TicketStub.com will fall under the entertainment umbrella.
• Lottery.com and Gaming: What began as the company’s sole business focus now forms a robust third pillar. The vertical includes Lottery.com’s global and domestic lottery operations, charitable gaming platform WinTogether, data provider Tinbu, and an expansion into iGaming, instant wins, and ethical sports betting.

Together, these pillars offer an integrated strategy that spans content, commerce, and gaming, all designed to foster fan engagement while delivering long-term value to shareholders.

A Turnaround Backed by Real Results

The rebrand is the latest step in a 24-month turnaround plan that has seen SEGG Media stabilize its balance sheet, restructure operations, and build an experienced leadership team. Among the most notable milestones:

• Appointment of experienced advisors and board members
• Expansion into asset-backed verticals
• A $300 million equity line of credit, which provides a foundation for non-dilutive growth and acquisition financing

According to Chairman Matthew McGahan, “SEGG Media isn’t just the end of a chapter; it’s the birth of a next-generation business.”

This evolution enables SEGG to compete with far larger legacy players, but with advantages in agility, technology, and a youth-oriented fan base.

What Comes Next: Growth, Globalization, and New Verticals

Looking ahead, SEGG Media has laid out an ambitious expansion roadmap. This includes:

• Launching Sports.com-branded physical venues and digital platforms globally
• Expanding presence in motorsports, esports, and sim racing markets
• Introducing new fashion and lifestyle verticals aimed at Gen Z and Millennial consumers
• Creating premium content and fan narratives through Sports.com Studios

These moves underscore the company’s focus on scalable brand assets and immersive experiences that go beyond traditional media and gaming.

Financial Strategy Centered on Sustainable Growth

SEGG Media’s financial playbook emphasizes revenue-generating acquisitions, responsible use of capital, and increasing shareholder value through strategic asset deployment. The $300 million equity line provides flexibility without immediate shareholder dilution, a rare feat for a company emerging from a restructuring phase.

With restructured debt, operational integrity, and a clear roadmap for diversified growth, SEGG Media enters this new phase with the tools to execute, expand, and differentiate.

Conclusion

SEGG Media Corporation’s launch marks more than the end of Lottery.com. It signals the emergence of a reimagined, financially backed, multi-vertical company built for a global audience. With a strategy rooted in innovation, ethical engagement, and digital storytelling, SEGG Media aims to redefine how fans experience the games, music, and moments they love. As the company moves forward with acquisitions, international growth, and next-gen content, it is positioning itself not just to survive in a rapidly changing media environment, but to lead it.

For more information, visit the company’s website at SEGGMediaCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to SEGG are available in the company’s newsroom at https://ibn.fm/SEGG

The National Investment Banking Association (“NIBA”) will host its 151st Investment Conference on September 16–17 in Ft. Lauderdale, Florida, uniting emerging growth companies with top-tier investors, fund managers, and industry leaders. Known for driving more than $100 billion in capital raises and facilitating 90% of all IPOs under $20 million, NIBA is creating a high-impact platform where innovative businesses can gain visibility, secure funding, and forge lasting partnerships.

The National Investment Banking Association (“NIBA”), a not-for-profit association dedicated to the micro-cap and small-cap investment community, is proud to announce the 151st edition of its flagship investment conference. Taking place September 16–17 in Ft. Lauderdale, Florida, the event will bring together public and private companies seeking capital with leading investors and financial professionals. Attendees will gain direct access to decision-makers, discover new opportunities, and build meaningful industry connections.

Since 1982, NIBA has served as a driving force for the micro-cap and small-cap sector. Its network includes more than 8,800 registered representatives and thousands of investment professionals representing over 60 specialized industry services. Collectively, these firms have raised more than $100 billion and are responsible for 90% of all IPOs under $20 million.

Over the past four decades, NIBA members have completed thousands of transactions, generating more than $100 billion in new capital for emerging growth companies. The association’s track record of connecting capital to innovation continues to shape industries across the United States and abroad. The 151st conference will provide attendees with valuable insights into current market trends, direct engagement with industry leaders, and a platform to position their companies for growth.

Registration is now open. Family offices, investment banks, and fund managers can register at no cost, while industry service providers can secure their place for just $350.

To learn more, please visit https://ibn.fm/LFdrS